Janus kinase inhibitors: a future all-rounder in axial spondyloarthritis?

References

• 1. Ramiro S, Nikiphorou E, Sepriano A et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann. Rheum. Dis. 82(1), 19–34 (2023).
  MedlineGoogle Scholar
• 2. Deodhar A, Sliwinska-Stanczyk P, Xu H et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 80(8), 1004–1013 (2021).
  Medline CASGoogle Scholar
• 3. van der Heijde D, Baraliakos X, Gensler LS et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet 392(10162), 2378–2387 (2018).
  MedlineGoogle Scholar
• 4. van der Heijde D, Song IH, Pangan AL et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet 394(10214), 2108–2117 (2019).
  MedlineGoogle Scholar
• 5. Deodhar A, Van den Bosch F, Poddubnyy D et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 400(10349), 369–379 (2022).
  Medline CASGoogle Scholar
• 6. van der Heijde D, Baraliakos X, Sieper J et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann. Rheum. Dis. 81(11), 1515–1523 (2022).
  MedlineGoogle Scholar
• 7. Deodhar A, van der Heijde D, Sieper J et al. Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: one-year results of a double-blind, placebo-controlled study and Open-label extension. Arthritis Rheumatol. 74(1), 70–80 (2022).
  Medline CASGoogle Scholar
• 8. van der Heijde D, Deodhar A, Maksymowych WP et al. Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension. RMD Open 8(2), e002280 (2022).
  MedlineGoogle Scholar
• 9. Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol. Hepatol. 7(2), 161–170 (2022).
  MedlineGoogle Scholar
• 10. Sandborn WJ, Feagan BG, Loftus EV Jr et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease. Gastroenterology 158(8), 2123–2138; e8 (2020).
  Medline CASGoogle Scholar
• 11. Harkins P, Burke E, Swales C, Silman A, Conway R. Are Janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis? A systematic review and meta-analysis. Int. J. Rheum. Dis. 26(1), 31–42 (2023).
  Medline CASGoogle Scholar
• 12. Foeldvari I, Maccora I, Petrushkin H et al. New and updated recommendations for the treatment of juvenile idiopathic arthritis-associated uveitis and idiopathic chronic anterior uveitis. Arthritis Care Res. (Hoboken) 75(5), 975–982 (2023).
  MedlineGoogle Scholar
• 13. Hecquet S, Valnet Rabier MB, Lepelley M et al. Ophthalmic adverse events under tofacitinib and baricitinib: case analysis of the European Pharmacovigilance Database. Joint Bone Spine 90(1), 105483 (2023).
  MedlineGoogle Scholar
• 14. Maccora I, Land P, Miraldi Utz V, Angeles-Han ST. Therapeutic potential of JAK inhibitors in juvenile idiopathic arthritis-associated uveitis. Expert Rev. Clin. Immunol. 19(7), 689–692 (2023).
  Medline CASGoogle Scholar
• 15. Schneider J, Schalenbourg A, Dudler J, Guex-Crosier Y. Intermediate uveitis in an HLA-B27-positive patient treated with upadacitinib. Klin. Monbl. Augenheilkd. 239(4), 572–574 (2022).
  MedlineGoogle Scholar
• 16. Joo W, Almario CV, Ishimori M et al. Examining treatment decision-making among patients with axial spondyloarthritis: insights from a conjoint analysis survey. ACR Open Rheumatol. 2(7), 391–400 (2020).
  MedlineGoogle Scholar
• 17. Lee SH, Kim YG, Lee SG et al. Treatment pattern, satisfaction, and productivity loss of patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors in Korea: a multicenter cross-sectional observational study. Int. J. Rheum. Dis. 25(5), 523–531 (2022).
  Medline CASGoogle Scholar
• 18. Nash P, Kerschbaumer A, Dörner T et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann. Rheum. Dis. 80(1), 71–87 (2021).
  Medline CASGoogle Scholar
• 19. Fang YF, Liu JR, Chang SH, Kuo CF, See LC. Comparative safety of Janus kinase inhibitors and tumor necrosis factor inhibitors in patients undergoing treatment for rheumatoid arthritis. Int. J. Rheum. Dis. 25(11), 1254–1262 (2022).
  Medline CASGoogle Scholar
• 20. Burmester GR, Cohen SB, Winthrop KL et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open 9(1), e002735 (2023).
  MedlineGoogle Scholar